Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab

Sponsor
Bristol-Myers Squibb
Study ID
NCT05170685
Status
No Longer Available

Eligibility Criteria

Sex
All
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is an expanded access designed to provide access to fixed-dose combination of nivolumab plus relatlimab for eligible participants.

Key Dates

Status verified
Apr 2022